respiratory
Cystic fibrosis

Drug combo a “game-changer” for cystic fibrosis


Lumacaftor in combination with ivacaftor provides clinically important reductions in the rate of pulmonary exacerbations in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation, new ground-breaking research shows. The phase 3 randomised double blind placebo controlled TRAFFIC and TRANSPORT trials of 1108 patients who were homozygous for the Phe508del mutation found the combination ...

Already a member?

Login to keep reading.


OR
© 2019 the limbic